Epstein Secrets

er at 28,363.66, the S&P 500 added 17.93 points to close at 3,453.49, and the Nasdaq climbed 21.31 points to 11,506.01. The AR (10/22, Choe, Troise, Veiga) and the Wall Street Journal (10/22, Bartholomew, Eisen, Subscription Publication, 7.57M), and Bloomberg (10/22, Haigh, 4.73M) provide similar cove

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

. The AP <https://www.usatoday.com/story/money/2020/10/22/us-stocks-flip-flop-amid-profit-reports-stimulus- talks/3727449001/> (10/22, Choe, Troise, Veiga) and the Wall Street Journal <https://www.wsj.com/articles/global-stock-markets-dow-update-10-22-2020-11603358278> (10/22, Bartholomew, Eisen, Subs

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

er at 28,363.66, the S&P 500 added 17.93 points to close at 3,453.49, and the Nasdaq climbed 21.31 points to 11,506.01. The AP (10/22, Choe, Troise, Veiga) and the Wall Street Journal (10/22, Bartholomew, Eisen, Subscription Publication, 7.57M), and Bloomberg (10/22, Haigh, 4.73M) provide similar cover

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug